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Abstract
Background: Prevalence estimates of cervical intraepithelial neoplasia (CIN) among HIV-infected women in India have been
based on cervical cytology, which may have underestimated true disease burden. We sought to better establish prevalence
estimates and evaluate risk factors of CIN among HIV-infected women in Pune, India using colposcopy and histopathology
as diagnostic tools.
Methodology: Previously unscreened, non-pregnant HIV-infected women underwent cervical cancer screening evaluation
including standardized diagnostic colposcopy by a gynecologist. Histopathologic confirmation was conducted among
consenting women with clinical suspicion of CIN. The prevalence of CIN was evaluated by a composite diagnosis based on
colposcopy and histopathology results. Multivariable ordinal logistic regression analysis was conducted to determine
independent predictors of increasing severity of CIN.
Results: The median age of the n=303 enrolled HIV-infected women was 30 years (interquartile range, 27–34). A majority of
the participants were widowed or separated (187/303, 61.7%), more than one-third (114/302, 37.7%) were not educated
beyond primary school, and nearly two-thirds (196/301, 64.7%) had a family per capita income of ,1,000 Indian Rupees
(,US$22)permonth. Cervical high-riskHPV-DNA wasdetected in41.7% (124/297)of participants.Thecompositecolposcopic-
histopathologic diagnoses revealed no evidence of CIN in 220 out of 303 (72.6%) women, CIN1 in 33/303 (10.9%), CIN2 in 31/
303 (10.2%), CIN3 in 18/303 (5.9%) and 1 (0.3%) woman was diagnosed with ICC. Thus, over a quarter of the participants [83/
303: 27.7% (95% CI: 22.7–33.1)] had $CIN1 lesions and a sixth [50/303: 16.5% (95% CI: 12.2–21.9)] had evidence of advanced
($CIN2)neoplasticdisease.The independent predictorsof increasingseverityof CIN as revealed bya proportionalodds model
using multivariable ordinal logistic regression included (i) currently receiving antiretroviral therapy [adjusted odds ratios (aOR):
2.24 (1.17, 4.26), p=0.01] and (ii) presence of cervical high-risk HPV-DNA [aOR: 1.93 (1.13, 3.28), p=0.02].
Conclusions: HIV-infected women in Pune, India have a substantial burden of cervical precancerous lesions, which may
progress to invasive cervical cancer unless appropriately detected and treated. Increased attention should focus on
recognizing and addressing this entirely preventable cancer among HIV-infected women, especially in the context of
increasing longevity due to antiretroviral therapy.
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Introduction
Women living with human immunodeficiency virus (HIV)
infection have a higher risk of human papillomavirus (HPV)-
associated cervical intraepithelial neoplasia (CIN) as compared to
HIV-uninfected women. [1,2] India has some of the highest case
burdens of both HIV/AIDS (estimated 2.4 million individuals,
including 1 million women) and cervical cancer (estimated
130,000 new cases and 74,000 deaths annually) of any single
nation.[3–5] The life span of HIV-infected women in India is
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8634increasing due to improved access to affordable antiretroviral
therapy (ART). [6] Before the introduction of ART, the lack of
cervical cancer prevention services probably had little influence on
the life expectancy of HIV-infected women due to high competing
mortality associated with other opportunistic infections. [7,8] As
HIV-infected women continue to live longer with ART support,
albeit in a moderately immunosuppressed state, they may be at
increased risk for CIN and invasive cervical cancer.[1,7]
Prior studies have reported an increased risk of cervical
intraepithelial neoplasia (CIN) in HIV-infected women in India
and other developing regions, but have almost entirely relied on
the detection of precancerous lesions using cervical cytology for
documenting prevalence.[9–12] However, with its low to moder-
ate sensitivity for detecting CIN, cytology may have underesti-
mated the true prevalence of CIN in HIV-infected women.[13,14]
Furthermore, even in clinical practice, an abnormality on cytology
needs confirmation by diagnostic colposcopy and further by
histopathology (if indicated) to reveal true disease status and plan
appropriate treatment.[15,16] It is important to assess the extent
of the disease burden through well-designed prevalence studies
that may inform targeting of scant resources for prevention
intervention activities. Unfortunately, no prior studies have
reported colposcopic-histopathologically confirmed prevalence of
CIN in HIV-infected women from India. We undertook a
descriptive epidemiology study in Pune, India to determine the
prevalence and predictors of colposcopic-histopathologically
confirmed CIN among HIV-infected women.
Methods
Study Setting and Participants
We developed an outpatient colposcopy clinic in a tertiary care
hospital in Pune, India. Study participation was offered to
consecutive HIV-infected women in a public-sector ART center
in the hospital premises. Participants were also recruited through
outreach efforts among self-help groups of HIV-infected women in
Pune city. Eligibility criteria included having documented
serologic evidence of HIV infection, negative urine pregnancy
test, absence of debilitating illness that may preclude a pelvic
examination, no prior history of screening or treatment for cervical
neoplasia, and no prior hysterectomy. Women with syndromic
evidence of sexually transmitted infections (STI) were initially
managed as per World Health Organization (WHO) guidelines
before continuing enrollment.[17] Participants were recruited
regardless of their CD4+ cell counts or current ART status.
Study Procedures
After explanation of study procedures and written informed
consent, a structured questionnaire was administered to interview
the participants and collect their sociodemographic information as
well as sexual and reproductive history (sexual behaviors, obstetric
history, menstrual history, past history of STI) and medical history
relevant to HIV/AIDS and cervical cancer. A blood sample was
obtained for CD4+ T-cell counts estimation [FACSCount
TM flow
cytometry, Becton, Dickinson and Company, Franklin Lakes, NJ,
USA]. All enrolled women underwent a complete physical, pelvic,
and colposcopic examination. Trained nurses collected endocervi-
cal samples that were tested for presence of high-risk HPV-DNA by
the Digene Hybrid Capture 2
TM (HC-2) assay [Qiagen, Inc.,
Gaithersburg, MD, USA] in a certified laboratory. [18] Nurses also
collected samples for Pap smears and performed visual inspection
with acetic acid (VIA) exam. All participants provided a self-
collected vaginal swab for HPV testing. (Results of the accuracy of
screening tests will be reported in a separate manuscript). A
standardized non-invasive colposcopy examination was performed
on all participants by gynecologists who recorded colposcopic
diagnosis using the Reid’s scoring index.[19] Invasive confirmatory
procedures [including cervical punch biopsies, endocervical curet-
tage (ECC), and loop electrosurgical excision procedures (LEEP)]
wereadvisedand performed on consentingparticipants withclinical
evidence of cervical abnormalities. Histopathology samples from
these procedures were analyzed independently by two experienced
pathologists who reported diagnosis by consensus. The final
diagnosis was based on (i) histopathology results for women in
whom invasive procedures were performed and (ii) diagnostic
colposcopy results in women who had no clinical indication for
undergoing invasive procedures, or in whom histopathology was
unavailable or inconclusive. Results were reported as per the
Richart CIN staging system in five categories of increasing disease
severity: normal/no neoplastic abnormalities, CIN1, CIN2, CIN3,
and invasive cervical cancer (ICC). [20] The study procedures and
results are summarized in the flow diagram. (Figure 1)
Statistical Methods
The statistical analyses were performed using R statistical
software (Version 2.9.1; http://www.r-project.org). The five-level
diagnostic categories were collapsed into a four-level ordinal
outcome variable of increasing neoplastic severity (i.e. no CIN,
CIN1, CIN2, and $CIN3) for statistical analyses. We evaluated
the predictors of increasing grade (severity) of CIN (on the ordered
outcome variable: no CIN, CIN1, CIN2, and $CIN3) using
bivariate (unadjusted) and multivariable ordinal logistic regression
analyses. Odds ratios (OR), 95% confidence intervals (CI) and
two-tailed p-values were calculated.[21] Ordinal logistic regression
assumes proportional odds – the association between predictor
variables and the odds of severe disease is constant regardless of
the CIN cut-off used to classify disease severity. This assumption
was visually inspected [22], and appeared reasonable. The
multivariable model included covariates found to be statistically
significant (p,0.05) on unadjusted analysis as well as those
deemed a priori to be most biologically salient to CIN incidence
and progression. To avoid over-fitting, the multivariable model
was limited to 10 covariates based on frequencies within the
ordered outcome variable.[23] For all models, continuous
covariates were first included in the model using restricted cubic
splines to avoid linearity assumptions. If the non-linear portions
did not prove to be significant, the model was refit assuming
linearity. We assumed that missing values occurred at random
given the other covariates and used multiple imputation to derive
predictions for missing values.[22] The extent of completeness of
data for various predictor variables is represented in Table 1.
Ethics Statement
The study protocol was approved by the institutional review
board of Vanderbilt University, and the ethics committees of the
National AIDS Research Institute (NARI) and Byramjee Jeejeeb-
hoy Medical College (BJMC). Scientific and administrative
approvals for this Indo-U.S. collaborative research study were
also received from the Scientific Advisory Committee of NARI
and the Indian Health Ministry Screening Committee, with
endorsement from the Indian National AIDS Control Organiza-
tion. All participants gave written informed consent.
Results
Sociodemographic Profile
Participation was offered to 319 HIV-infected women between
October 2006 and September 2007, of whom two each (0.6%
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315 eligible persons, 303 (96%) enrolled with informed consent.
The median age was 30 years (interquartile range, IQR: 27–34). A
majority of the participants were widowed or separated (187/303,
61.7%) as opposed to cohabiting with their husbands or spouses
(116/303, 38.3%). More than one-third of the participants (114/
302, 37.7%) were not educated beyond primary school and nearly
two-thirds (196/301, 64.7%) had a family per capita income of less
than 1,000 Indian Rupees (approximately US$22 at the time) per
month. A large majority of the participants (260/297, 87.5%)
reported only one lifetime sexual partner. The median reported
age at first sexual intercourse was 18 years (IQR: 15–19), median
age of menarche was 13 years (IQR: 13–14) and the median
number of births per woman was 2 (IQR: 1–3). The median
CD4+ T-cell count was 343/mL (IQR: 244–495) and a large
majority (262/303; 86.5%) presented with WHO Clinical Stage I/
II of HIV/AIDS. About one quarter of women (70/271, 25.8%)
were on ART at the time of enrollment; however, detailed data
were not available on ART regimen or their duration of
treatment. Cervical high-risk HPV-DNA (by the HC-2 assay)
was detected in nurse-collected cervical swabs in about two-fifths
[41.7% (124/297)] of the participants.
Cervical Disease Prevalence
Colposcopy was performed on all participants and revealed no
evidence of CIN in 223 women, CIN1 in 17 women, CIN2 in 27
women, and CIN3 in 36 women. No cases of ICC were detected
on colposcopy. Invasive diagnostic procedures for histopathology
were indicated in a total of 73/303 (24.1%) women undergoing
colposcopy. This included 63 women with the protocol defined
threshold of offering histopathological confirmatory procedures for
evidence of $CIN2 on colposcopy [36 women with CIN3 and 27
women with CIN2], as well as in 10 women for whom the clinician
deemed that histopathology was necessary [including 4 women
Figure 1. Study enrollment, procedures, and main outcomes. The flow diagram shows the number of HIV-infected women who were offered
participation, those enrolled in thestudy,list of study procedures,andfinaldiagnosisthrough the compositecolposcopic-histopathologicalassessment.
doi:10.1371/journal.pone.0008634.g001
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diagnoses) among HIV-infected women in Pune, India.
Covariates Overall Normal CIN1 CIN2 CIN3 and ICC
Overall 100% (303) 72.6% (220) 10.9% (33) 10.2% (31) 6.3%(19)
Age n=303
Median (IQR) (years) 30 (27, 34) 30 (27,33.3) 32(28,36) 29(25,31.5) 31(28,40)
Education n=302
No/some primary education 38% (114) 34% (75) 39% (13) 52% (16) 53% (10)
High school or above 62% (188) 66% (144) 61% (20) 48% (15) 47% (9)
Marital status n=303
Cohabiting with husband/spouse 38% (116) 37% (82) 24% (8) 55% (17) 47% (9)
widowed/separated 62% (187) 63% (138) 76% (25) 45% (14) 53% (10)
Family income n=301
,INR 1,000
‘/month/person 65% (196) 66% (144) 64% (21) 61% (19) 63% (12)
$INR 1,000
‘/month/person 35% (105) 34% (74) 36% (12) 39% (12) 37% (7)
Occupation n=302
Employed/Professional 66% (200) 68% (148) 61% (20) 61% (19) 68% (13)
Unemployed/Housewife 34% (102) 32% (71) 39% (13) 39% (12) 32% (6)
Age at first sex n=298
Median (IQR) (years) 18 (15, 19) 18 (16,19) 18 (15,19) 17 (15,18) 16 (15.3,17)
Age at menarche n=299
Median (IQR) (years) 13 (13, 14) 13(13,14) 14 (13,15) 13 (12,14) 13.5 (13,14)
Lifetime sexual partners n=297
$2 partners 13% (37) 10% (21) 27% (9) 20% (6) 6% (1)
1 partner 87% (260) 90% (196) 73% (24) 80% (24) 94% (16)
HIV status of partner n=300
HIV-infected spouse 31% (92) 29% (64) 18% (6) 48% (15) 37% (7)
No HIV-infected spouse 69% (208) 71% (153) 82% (27) 52% (16) 63% (12)
Condom Use frequency n=118
Not using/inconsistent user 45% (53) 47% (40) 43% (3) 35% (6) 50% (4)
Consistent/always user 55% (65 ) 53% (46) 57% (4) 65% (11) 50% (4)
History of past STI n=303
Yes, history of past STI 32% (96) 31% (68) 33% (11) 39% (12) 26% (5)
No history of past STI 68% (207) 69% (152) 67% (22) 61% (19) 74% (14)
Use of tobacco products n=303
Current user/used in past 40% (122) 41% (91) 33% (11) 35% (11) 47% (9)
Never used 60% (181) 59% (129) 67% (22) 65% (20) 53% (10)
Used hormonal
contraceptive $1 year
n=303
Used $1 year 8% (25) 8% (17) 9% (3) 10% (3) 11% (2)
Not used/used ,1 yr 92% (278) 92% (203) 91% (30) 90% (28) 89% (17)
Number of births n=299
Median (IQR) 2 (1,3) 2 (1,3) 2 (1,3) 2 (1,3) 3 (2,3)
Months since HIV detection n=151
Median (IQR) 23 (5,39) 23 (6, 38) 31 (13, 45) 9 (3, 33) 25 (8, 37)
Presence of gynecological
symptoms
n=303
Symptoms present currently 90 (30%) 31% (68) 27% (9) 26% (8) 26% (5)
No symptoms present currently 213 (70%) 69% (152) 73% (24) 74% (23) 74% (14)
Body Mass Index n=303
Median (IQR) 19.4(17.8,21.3) 19.4 (17.8,21.2) 19.2 (18,21.5) 19.7 (17.8,20.7) 19.7 (17.1,22.4)
CD4+ T-cell count n=293
Median (IQR) (/mL) 343 (241,497) 355 (260, 497) 343 (252, 500) 264 (183, 510) 327 (237,400)
Cervical Neoplasia and HIV
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women having colposcopic CIN1 lesions with suspicion of
endocervical extension of lesions that prompted need for
histopathological confirmation]. (Table 2)
Of the 73 women for whom histopathology was recommended,
59 actually underwent the procedures, which included 29 out of 36
with CIN3 on colposcopy, 20 out of 27 with CIN2 on colposcopy,
and all 10 with clinical indications for undergoing histopathology.
Fourteen participants (7 with CIN2 and 7 with CIN3) did not
consent to undergo histopathological confirmatory procedures.
(The most common cited reason was the necessity to consult with
their family members or spouses before undergoing an invasive
procedure. In spite of efforts by study staff to recall them for a
follow-up visit to undergo the procedures, these 14 participants did
not return.) Histopathological results were reported as ‘‘inconclu-
sive’’ in 2 participants (having CIN2 lesions on colposcopy) for
whom there were no possibility of recall for repeat procedures.
Thus, the colposcopy results served as the final diagnosis in 246/
303 (81.2%) women, which included the 14 participants who
refused the invasive procedures and 2 participants with inconclu-
sive histopathology results. Histopathology results, available in 57/
303 (18.8%) participants revealed 1 woman with no evidence of
CIN, 22 women with CIN1, 22 women with CIN2, 11 women
with CIN3, and a singular case of ICC (a participant who had
CIN3 impression on colposcopy). (Table 2)
The final composite colposcopic-histopathologic diagnoses
revealed no abnormality (no evidence of CIN) in 220 out of 303
(72.6%) women. CIN1 was reported in 33 (10.9%) women, CIN2
in 31 (10.2%) women, CIN3 in 18 (5.9%) women, while 1 (0.3%)
woman was diagnosed with ICC. (Table 3) Thus, more than 1 in 4
women [83/303: 27.7% (95% CI: 22.7–33.1)] had colposcopic-
histopathological evidence of $CIN1 lesions and 1 in 6 women
[50/303: 16.5% (95% CI: 12.2–21.9)] had evidence of advanced
($CIN2) neoplastic disease.
Predictors of Increasing Severity of CIN
In unadjusted (bivariate) analysis, participants with greater odds
of more severe CIN included those currently receiving ART, those
with cervical high-risk HPV-DNA, those with two or more lifetime
sexual partners (marginally significant) and those educated only up
to the primary school level. (Table 4) On multivariable ordinal
logistic regression analysis, the independent predictors of having
Covariates Overall Normal CIN1 CIN2 CIN3 and ICC
WHO Stage n=303
Stage III/IV 14% (41) 13% (29) 12% (4) 13% (4) 21% (4)
Stage I/II 87% (262) 87% (191) 88% (29) 87% (27) 79% (15)
ART status n=271
Currently receiving ART 26% (70) 21% (42) 38% (11) 25% (7) 67% (10)
ART-naı ¨ve 74% (201) 79% (157) 62% (18) 75% (21) 33% (5)
Presence of cervical
high-risk HPV DNA
n=297
high-risk HPV-DNA positive 42% (124) 37% (80) 52% (17) 50% (15) 67% (12)
high-risk HPV DNA negative 58% (173) 63% (136) 48% (16) 50% (15) 33% (6)
Abbreviations: IQR: interquartile ratio (25th percentile and 75th percentile), INR: Indian Rupees; BMI: Body Mass Index; ART: Antiretroviral therapy; STI: Sexually
transmitted infection; WHO: World Health Organization.
‘The exchange rate at the time of the study was approximately 45 INR (Indian Rupees) per US$ such that Indian Rupees 1,000 are the equivalent of US$ 22.
doi:10.1371/journal.pone.0008634.t001
Table 1. Cont.
Table 2. Distribution of the histopathologic diagnoses stratified by colposcopy results among HIV-infected women in Pune, India.
Colposcopy results
No CIN CIN1 CIN2 CIN3 ICC Total
Histopathologic diagnoses
No Histopathology done 219 11 7 7 0 244
Histopathology inconclusive 0 0 2 0 0 2
No CIN 0 0 0 1 0 1
CIN1 2* 4
‘ 97 0 2 2
CIN2 2* 1
‘ 61 3 0 2 2
CIN3 0 1
‘ 37 0 1 1
ICC 0 0 0 1 0 1
223 17 27 36 0 303
*=these 4 participants were indicated histopathological confirmation due to an ‘‘unsatisfactory’’ colposcopic examination result.
‘=these 6 participants had CIN1 lesions on colposcopy but the clinician suspected endocervical lesions prompting histopathological confirmation.
doi:10.1371/journal.pone.0008634.t002
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[adjusted odds ratios (aOR): 2.24 (95% CI: 1.17, 4.26), p=0.01]
as compared to being ART-naı ¨ve, and (ii) having presence of
cervical high-risk HPV-DNA [aOR: 1.93 (1.13, 3.28), p=0.01] as
opposed to being cervical high-risk HPV-DNA-negative. (Table 4)
HIV-infected women with primary school education or lower
[aOR: 1.85 (0.97, 3.51), p=0.06] and those with two or more
lifetime sexual partners [aOR: 1.80 (0.91, 3.59), p=0.09] also had
greater odds of more severe CIN, but these associations were only
marginally statistically significant. (Table 4)
Discussion
Our study is the first report from India on CIN disease
prevalence in HIV-infected women confirmed by a composite
colposcopic-histopathological assessment. Previous studies have
relied on the use of cytology to report prevalence of CIN in HIV-
infected women.[9–12]. The cytology-derived prevalence esti-
mates in these studies have varied according to the population
being sampled, ranging from 6.3% (voluntary counseling and
testing clinics, n=287),[11] 14% (HIV and gynecology clinics,
n=75),[12] 19.2% (women attending STI clinics, n=100),[9] to
Table 3. Distribution of the ‘‘composite’’ colposcopic
histopathological diagnoses by the confirmatory diagnostic
procedure (colposcopy or histopathology) among HIV-
infected women in Pune, India.
Result based on
Histopathology
diagnoses
Result based on
Colposcopy
results
Final ‘‘Composite’’
diagnosis
No CIN=220 1 219
CIN1=33 22 11
CIN2=31 22 9
CIN3=18 11 7
ICC=1 1 0
Total=303 57 246
doi:10.1371/journal.pone.0008634.t003
Table 4. Unadjusted (bivariate) and multivariable ordinal logistic regression analysis of predictors of disease prevalence for ordinal
outcome in three categories of increasing disease severity (No CIN, CIN1, CIN2, $CIN3) confirmed by composite colposcopic-
histopathological diagnosis among HIV-infected women in Pune, India.
Unadjusted (bivariate) ordinal logistic
regression analysis
Multivariable ordinal logistic
regression analysis*
OR (95% CI) p-value Adjusted OR (95% CI) p-value
Unit (1-year) increase in age (e.g., 28 vs. 27 years) 1.03 (0.99, 1.08) 0.15 1.01 (0.96, 1.06) 0.71
No/some primary education (vs. $high school) 1.76 (1.06, 2.91) 0.03 1.85 (0.98, 3.51) 0.06
Cohabiting with husband/spouse (vs. $widowed/separated) 1.28 (0.77, 2.13) 0.34 Not included –
Family income ,INR 1,000/month/person (vs. $INR 1,000)
‘ 0.86 (0.51, 1.45) 0.58 0.85 (0.48, 1.51) 0.59
Employed/Professional (vs. unemployed/housewife) 0.83 (0.49, 1.39) 0.48 Not included –
Unit (1-yr) increase in age at first sex (e.g.,18 vs. 17 yrs) 0.94 (0.86, 1.02) 0.14 0.98 (0.89, 1.09) 0.72
Unit (1-yr) increase in age at menarche (e.g.,13 vs. 12 yrs) 1.03 (0.85, 1.24) 0.80 Not included –
$2 lifetime sexual partners (vs. single lifetime partner) 1.91 (0.98, 3.73) 0.06 1.80 (0.91, 3.59) 0.09
HIV-infected spouse (vs. no HIV-infected spouse) 1.33 (0.78, 2.26) 0.30 Not included –
No/inconsistent condom use (vs. consistent use) 0.81 (0.36, 1.82) 0.61 Not included –
History of presence of STI (vs. no STI) 1.12 (0.66, 1.89) 0.68 Not included –
Ever used tobacco products (vs. never users) 0.88 (0.53, 1.48) 0.64 Not included –
Hormonal contraceptive $1 year (vs. not used/used ,1 yr) 1.28 (0.54, 3.04) 0.57 Not included –
Unit increase in number of births (e.g., 3 vs. 2 births) 1.06 (0.87, 1.30) 0.55 0.99 (0.79, 1.25) 0.93
Unit incr. in months since HIV detection (e.g., 13 vs. 12) 0.94 (0.78, 1.13) 0.48 Not included –
Presence of gynecological symptoms (vs. no symptoms) 0.81 (0.46, 1.41) 0.45 Not included –
Unit increase in BMI (e.g., 20 vs. 19) 0.99 (0.91, 1.08) 0.82 Not included –
100 unit increase in CD4+ count (/mL) (e.g., 350 vs. 250) 0.92 (0.81, 1.04) 0.18 0.96 (0.84, 1.10) 0.55
WHO Stage III/IV (vs. WHO Stage I/II) 1.17 (0.57, 2.40) 0.67 1.07 (0.50, 2.32) 0.86
Currently receiving ART (vs. ART-naı ¨ve) 2.48 (1.40, 4.40) ,0.01 2.24 (1.17, 4.26) 0.01
Presence of cervical high-risk HPV DNA (vs. no high-risk HPV DNA) 2.06 (1.24, 3.42) ,0.01 1.93 (1.13, 3.28) 0.02
Abbreviations: OR: Odds ratio; CI: Confidence intervals; INR: Indian Rupees; BMI: Body Mass Index; ART: Antiretroviral therapy; STI: Sexually transmitted infection; WHO:
World Health Organization.
*The number of covariates that could be included in the multivariable regression model was dependent on the number of event outcomes for that analysis to avoid
over-fitting of the models. Hence only 10 covariates were included in the multivariable model. Covariates were deemed scientifically important and selected a priori
along with covariates that were significant in unadjusted (bivariate) analysis.
‘The exchange rate at the time of the study was approximately 45 INR (Indian Rupees) per US$ such that Indian Rupees 1,000 are the equivalent of US$ 22.
doi:10.1371/journal.pone.0008634.t004
Cervical Neoplasia and HIV
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e863430.7% (commercial sex workers, n=137),[9]. However, cervical
cytology (Pap smear) has only moderate sensitivity in detecting
CIN and may miss many lesions.[13,14] Besides, ‘true’ CIN
disease estimation is only done by standardized diagnostic
confirmatory colposcopy followed by histopathological confirma-
tion as may be indicated clinically. [15,16] All participants in our
study received a standardized diagnostic colposcopic examination.
Additional invasive confirmatory diagnostic procedures (biopsy,
LEEP, ECC) were restricted only for consenting women with
clinical evidence of CIN, as per internationally recommended
clinical management guidelines.[24] This approach avoided
unnecessary invasive diagnostic procedures yet increased the
accuracy of CIN diagnosis more than from diagnostic colposcopy
alone.[24,25] Thus, our study design represents the best effort for
maximizing the precision of clinical-pathological prevalence
estimates while balancing ethical concerns by avoiding unneces-
sary invasive procedures. The participant recruitment in this study
was undertaken regardless of the baseline CD4+ cell counts or
presence of symptoms of cervical cancer or HIV/AIDS. This, and
the fact that none of the participants had been previously screened
or treated for cervical neoplasia, has limited the selection bias in
our study and increased the generalizability and representativeness
of our findings for HIV-infected women in India.
A limitation of our data was that we were not able to extract
complete data on duration of ART or type of ART regimens.
While national guidelines in India suggest that ART be initiated if
nadir CD4+ cell counts fall under 200/mL or if there is presence of
AIDS-defining illness, our data only includes the CD4+ cell counts
at the time of enrollment (as opposed to nadir CD4+ cell counts).
In our multivariable analyses, currently receiving ART for HIV/
AIDS was an independent predictor of CIN, even after controlling
for current CD4+ T-cell counts and stage of HIV disease. While
evidence on the impact of ART on the natural history of CIN in
HIV-infected women is limited, most studies have pointed that
immune reconstitution due to ART has minimal or no impact on
the progression of CIN. [26,27] Thus, as HIV-infected women in
India and elsewhere in the developing nations start living longer
on ART in a moderately immunosuppressed state, they may
continue to be at risk for slowly progressing cervical neoplasia
associated with persistent HPV infection unless preventive
interventions are instituted.
Our study also confirms the high prevalence (41.7%) of high-risk
HPV-DNA in this population, as well as the presence of HPV as an
independent predictor of CIN, as observed in multiple studies
among HIV-infected women worldwide.[28–30] Although HPV-
DNAtesting currently remainsunavailable or unaffordable formost
womeninIndiaandotherdevelopingcountries,thereisasignificant
global push toward the introduction of low-cost, rapid HPV testing
in developing countries that may allow better diagnostic options for
CIN, especially for high-risk HIV-infected women.[31,32]
Our study has several limitations. Colposcopy and histopathol-
ogy results are by nature rater-dependent and subjective
interpretations.[33–38] We tried to address this limitation by
standardizing the interpretation of colposcopic diagnoses (using
Reid’s scoring index) and incorporating quality assurance of
colposcopic images by a senior experienced gynecologist (RB). The
histopathology reports were read by two independent pathologists
(AK, CN) who initially analyzed each histopathology slide and
then reconciled differences and reported results by consensus. Yet
the possibility of misclassification of lesions cannot be eliminated
completely, especially considering the transitory nature of HPV
infection and low grade (CIN1) lesions in HIV-infected wom-
en.[39] Also, some experts have recommended use of invasive
cervical biopsy for histopathology even from normal looking areas
of the cervix during colposcopy for improved diagnostic accuracy
rather than using selective directed histopathology of colposcop-
ically abnormal appearing lesions alone.[40,41] While we
performed ECC whenever possible in situations where colposcopy
did not reveal abnormalities, our study protocol emphasized the
avoidance of unnecessary invasive procedures to prevent risk of
iatrogenic infection and untoward blood loss in our cohort of HIV-
infected women. This may have led us to overly rely on
colposcopic assessment as opposed to histopathological assessment
in a majority of our participants. Yet, performing invasive
procedures from normal appearing parts of the cervix is
controversial, and there is clearly a role for improving disease
ascertainment through non-invasive novel screening and diagnos-
tic tools.[32,42] Finally, the cross-sectional nature of this study
allows the possibility for uncontrolled confounding and also
precludes any attempt for deriving causality. Indeed, this
underscores the need for conducting well-designed prospective
cohort studies to study natural history of cervical neoplasia among
HIV-infected women in developing country settings. We have
initiated prospective evaluation of this cohort and established
similar study cohorts in both urban and rural sites in other high-
prevalence settings in India that may also improve the general-
izability of our findings.
The need for cervical cancer screening services for this
population, as evidenced by the high prevalence of advanced
cervical neoplasia in this study ($CIN1: 27.7% and $CIN2:
16.6%), is enormous. Yet the population coverage of cervical
cancer prevention programs in India and most developing
countries is largely inadequate.[43,44] While limitations in
initiating and sustaining services for cervical cancer prevention
services are key concerns, the coverage is also poor since a
majority of women in these settings hardly access clinical care, let
alone preventive care.[45] Fortunately, HIV/AIDS care and
treatment programs represent a potential window of opportunity
for providing preventive clinical interventions to avert a cervical
cancer epidemic nested within the HIV pandemic. We believe that
providing cost-effective, life-saving cervical cancer prevention
services linked to HIV care (much like screening and treatment
for tuberculosis and other opportunistic infections) must be a
global imperative for HIV-infected women who have an elevated
risk for this entirely preventable malignancy.[46,47] In the context
of the global economic downturn and the resulting challenges in
public health allocations, integrated sexual and reproductive
health care programs such as HIV/AIDS care and cervical
cancer prevention may allow efficient utilization of resources for
improving health care access for those most vulnerable to these
eminently preventable diseases.
Acknowledgments
We thank Dr. Eric Chamot and Dr. Groesbeck Parham for advice and
guidance for protocol development, Dr. Santosh Jaybhaye and Dr. Nayana
Dhage for clinical care of participants, and Mr. Avinash Gaikwad for data
management support. We thank all HIV-infected women who participated
in this study.
Author Contributions
Conceived and designed the experiments: VVS SNJ SS ARR SHV SM.
Performed the experiments: VVS RAB ANK CAN RSK ARR. Analyzed
the data: VVS RSK CAJ BS SHV SM. Contributed reagents/materials/
analysis tools: VVS RAB SNJ ANK CAN RSK CAJ BS SS ARR SHV
SM. Wrote the paper: VVS RAB SNJ ANK CAN RSK CAJ BS SS ARR
SHV SM.
Cervical Neoplasia and HIV
PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8634References
1. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, et al. (2005) Natural
history and possible reactivation of human papillomavirus in human
immunodeficiency virus-positive women. J Natl Cancer Inst 97: 577–586.
2. Palefsky JM, Holly EA (2003) Chapter 6: Immunosuppression and co-infection
with HIV. J Natl Cancer Inst Monogr. pp 41–46.
3. Dhir AA, Sawant SP (2008) Malignancies in HIV: the Indian scenario. Curr
Opin Oncol 20: 517–521.
4. UNAIDS (2007) 2007 AIDS Epidemic Update. Joint United Nations
Programme on HIV/AIDS.
5. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA
Cancer J Clin 55: 74–108.
6. Over M, Marseille E, Sudhakar K, Gold J, Gupta I, et al. (2006) Antiretroviral
therapy and HIV prevention in India: modeling costs and consequences of
policy options. Sex Transm Dis 33: S145–152.
7. Franceschi S, Jaffe H (2007) Cervical cancer screening of women living with HIV
infection: a must in the era of antiretroviral therapy. Clin Infect Dis 45: 510–513.
8. Ghate M, Deshpande S, Tripathy S, Nene M, Gedam P, et al. (2008) Incidence of
commonopportunisticinfectionsinHIV-infectedindividualsinPune,India:analysis
by stages of immunosuppression represented by CD4 counts. Int J Infect Dis.
9. Joshi J, Mali B, Bhave G, Wagle U (1993) Cervical neoplasia and cytological
manifestations of sexually transmitted diseases in HIV-seropositive prostitutes.
Cytopathology 4: 63–64.
10. Joshi S, Chandorkar A, Krishnan G, Walimbe A, Gangakhedkar R, et al. (2001)
Cervical intraepithelial changes & HIV infection in women attending sexually
transmitted disease clinics in Pune, India. Indian J Med Res 113: 161–169.
11. Joshi SN, Gopalkrishna V, Kumar BK, Dutta S, Nyaynirgune P, et al. (2005)
Cervical squamous intra-epithelial changes and human papillomavirus infection
in women infected with human immunodeficiency virus in Pune, India. J Med
Virol 76: 470–475.
12. Peedicayil A, Thiyagarajan K, Gnanamony M, Pulimood SA, Jeyaseelan V, et
al. (2009) Prevalence and risk factors for human papillomavirus and cervical
intraepithelial neoplasia among HIV-positive women at a tertiary level hospital
in India. J Low Genit Tract Dis 13: 159–164.
13. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, et al. (2000)
Accuracy of the Papanicolaou test in screening for and follow-up of cervical
cytologic abnormalities: a systematic review. Ann Intern Med 132: 810–819.
14. Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S (2005) A critical
assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 89
Suppl 2: S4–S12.
15. Jordan J, Arbyn M, Martin-Hirsch P, Schenck U, Baldauf JJ, et al. (2008)
European guidelines for quality assurance in cervical cancer screening:
recommendations for clinical management of abnormal cervical cytology, part
1. Cytopathology 19: 342–354.
16. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, et al. (2007)
2006 consensus guidelines for the management of women with abnormal
cervical cancer screening tests. Am J Obstet Gynecol 197: 346–355.
17. World Health Organization (2003) Guidelines for the management of sexually
transmitted infections. Geneva, Switzerland: World Health Organization.
18. Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, et al. (2001)
Detection of high-risk HPV types by the hybrid capture 2 test. J Med Virol 65:
155–162.
19. Sellors JW, Sankaranarayanan R, International Agency for Research on Cancer
(2003) Colposcopy and treatment of cervical intraepithelial neoplasia: a
beginner’s manual. Lyon, France: International Agency for Research on Cancer.
20. Richart RM (1973) Cervical intraepithelial neoplasia. Pathol Annu 8: 301–328.
21. Armstrong BG, Sloan M (1989) Ordinal regression models for epidemiologic
data. Am J Epidemiol 129: 191–204.
22. Harrell FE (2001) Regression modeling strategies: with applications to linear
models, logistic regression, and survival analysis. New York: Springer.
23. Harrell FE Jr, Lee KL, Matchar DB, Reichert TA (1985) Regression models for
prognostic prediction: advantages, problems, and suggested solutions. Cancer
Treat Rep 69: 1071–1077.
24. Dexeus S, Cararach M, Dexeus D (2002) The role of colposcopy in modern
gynecology. Eur J Gynaecol Oncol 23: 269–277.
25. Kosinski AS, Barnhart HX (2003) Accounting for nonignorable verification bias
in assessment of diagnostic tests. Biometrics 59: 163–171.
26. Heard I, Palefsky JM, Kazatchkine MD (2004) The impact of HIV antiviral
therapy on human papillomavirus (HPV) infections and HPV-related diseases.
Antivir Ther 9: 13–22.
27. Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, et al. (2001) The effect
of highly active antiretroviral therapy on cervical cytologic changes associated
with oncogenic HPV among HIV-infected women. Aids 15: 2157–2164.
28. Hawes SE, Critchlow CW, Sow PS, Toure P, N’Doye I, et al. (2006) Incident
high-grade squamous intraepithelial lesions in Senegalese women with and
without human immunodeficiency virus type 1 (HIV-1) and HIV-2. J Natl
Cancer Inst 98: 100–109.
29. Denny L, Boa R, Williamson AL, Allan B, Hardie D, et al. (2008) Human
papillomavirus infection and cervical disease in human immunodeficiency virus-
1-infected women. Obstet Gynecol 111: 1380–1387.
30. Parham GP, Sahasrabuddhe VV, Mwanahamuntu MH, Shepherd BE,
Hicks ML, et al. (2006) Prevalence and predictors of squamous intraepithelial
lesions of the cervix in HIV-infected women in Lusaka, Zambia. Gynecol Oncol
103: 1017–1022.
31. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, et al. (2008) A new HPV-DNA
test for cervical-cancer screening in developing regions: a cross-sectional study of
clinical accuracy in rural China. Lancet Oncol 9: 929–936.
32. Gravitt PE, Coutlee F, Iftner T, Sellors JW, Quint WG, et al. (2008) New
technologies in cervical cancer screening. Vaccine 26 Suppl 10: K42–52.
33. Ballagh S (2004) Factors affecting the reproducibility and validity of colposcopy
for product development: review of current literature. J Acquir Immune Defic
Syndr 37 Suppl 3: S152–155.
34. Massad LS, Schneider M, Watts H, Darragh T, Abulafia O, et al. (2001)
Correlating Papanicolaou Smear, Colposcopic Impression, and Biopsy: Results
from the Women’s Interagency HIV Study. J Low Genit Tract Dis 5: 212–218.
35. McCluggage WG, Bharucha H, Caughley LM, Date A, Hamilton PW, et al.
(1996) Interobserver variation in the reporting of cervical colposcopic biopsy
specimens: comparison of grading systems. J Clin Pathol 49: 833–835.
36. Stoler MH, Schiffman M (2001) Interobserver reproducibility of cervical
cytologic and histologic interpretations: realistic estimates from the ASCUS-
LSIL Triage Study. JAMA 285: 1500–1505.
37. McCluggage WG, Walsh MY, Thornton CM, Hamilton PW, Date A, et al.
(1998) Inter- and intra-observer variation in the histopathological reporting of
cervical squamous intraepithelial lesions using a modified Bethesda grading
system. Br J Obstet Gynaecol 105: 206–210.
38. Jeronimo J, Schiffman M (2006) Colposcopy at a crossroads. Am J Obstet
Gynecol 195: 349–353.
39. Massad LS, Evans CT, Strickler HD, Burk RD, Watts DH, et al. (2005)
Outcome after negative colposcopy among human immunodeficiency virus-
infected women with borderline cytologic abnormalities. Obstet Gynecol 106:
525–532.
40. Pretorius RG, Bao YP, Belinson JL, Burchette RJ, Smith JS, et al. (2007)
Inappropriategold standard bias in cervical cancerscreening studies. Int JCancer
121: 2218–2224.
41. Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, et al. (2004)
Colposcopically directed biopsy, random cervical biopsy, and endocervical
curettage in the diagnosis of cervical intraepithelial neoplasia II or worse.
Am J Obstet Gynecol 191: 430–434.
42. Gage JC, Hanson VW, Abbey K, Dippery S, Gardner S, et al. (2006) Number of
cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 108: 264–272.
43. Gakidou E, Nordhagen S, Obermeyer Z (2008) Coverage of cervical cancer
screening in 57 countries: low average levels and large inequalities. PLoS Med 5:
e132.
44. Sankaranarayanan R, Bhatla N, Gravitt PE, Basu P, Esmy PO, et al. (2008)
Human papillomavirus infection and cervical cancer prevention in India,
Bangladesh, Sri Lanka and Nepal. Vaccine 26 Suppl 12: M43–52.
45. Patro BK, Nongkynrih B (2007) Review of screening and preventive strategies
for cervical cancer in India. Indian J Public Health 51: 216–221.
46. Mwanahamuntu MH, Sahasrabuddhe VV, Stringer JS, Parham GP (2008)
Integrating cervical cancer prevention in HIV/AIDS treatment and care
programmes. Bull World Health Organ 86: D–E.
47. Mwanahamuntu MH, Sahasrabuddhe VV, Parham GP (2009) HPV screening
for cervical cancer in rural India. N Engl J Med 361: 305; author reply 306.
Cervical Neoplasia and HIV
PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8634